Notably, daunorubicin sensitivity increases NPM1-mutated AML cells’ post-treatment sensitivity to ATO-ATRA, showing promise as possible sensitisers for leukemic cells before chemotherapy [141]. Here, NPM1 is linked to acute myeloid leukemia.